Stocks
Neurocrine Biosciences (NBIX) EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | 226.6 | 336.1 | 218.7 | 264.6 | 416.1 | 619.5 | ||
| Changes by years, y/y, % | +514% | +48% | -35% | +21% | +57% | +62.3% | |||
Neurocrine Biosciences. EBITDA US GAAP, bln rub
Neurocrine Biosciences. EBITDA US GAAP, changes, %
Neurocrine Biosciences. EBITDA US GAAP, sum by quarters, bln rub
Neurocrine Biosciences (NBIX) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA, bln rub | ? | 146.7 | 156.0 | 111.5 | 155.2 | 196.8 | 619.5 | |
| Changes by years, y/y, % | +60% | +51% | +275% | +111% | +34% | |||
| Changes by quarters, q/q, % | +99% | +6% | -29% | +39% | +27% | |||
